Anti-FGD5 / FYVE, RhoGEF and PH domain-containing protein 5

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The FGD5 antibody targets FYVE, RhoGEF, and PH domain-containing protein 5, a guanine nucleotide exchange factor encoded by the FGD5 gene. This protein belongs to the FGD family of Rho guanine nucleotide exchange factors (GEFs) that activate CDC42, a small GTPase involved in cytoskeletal organization, vesicle trafficking, and angiogenesis. FYVE, RhoGEF, and PH domain-containing protein 5 is enriched in endothelial cells and plays a critical role in vascular development and remodeling. The FGD5 antibody enables detection and quantification of this signaling molecule, supporting research into endothelial cell biology and vascular homeostasis.FGD5 contains multiple conserved domains, including a FYVE domain that binds phosphatidylinositol 3-phosphate, a Dbl homology (DH) domain that catalyzes GTP loading of CDC42, and a pleckstrin homology (PH) domain that anchors the protein to membranes. These domains coordinate spatial activation of CDC42 at specific cellular sites, promoting actin cytoskeletal rearrangements necessary for cell migration and tube formation. The FGD5 antibody provides a key reagent for examining how this protein localizes to endosomes and plasma membrane regions during angiogenic signaling.Endothelial FGD5 regulates cell polarity, barrier integrity, and lumen formation by activating CDC42 and downstream effectors such as PAK and N-WASP. Its expression is induced by vascular growth factors, including VEGF and FGF, which drive endothelial morphogenesis. The FGD5 antibody supports studies into these processes, helping delineate how Rho GTPase signaling orchestrates angiogenic sprouting and vessel stabilization. Loss of FGD5 function leads to impaired vascular network formation, highlighting its essential developmental role.Beyond angiogenesis, FYVE, RhoGEF, and PH domain-containing protein 5 contributes to intracellular trafficking and signal transduction in other tissues, including kidney and brain. Abnormal FGD5 expression has been linked to vascular pathologies, diabetic retinopathy, and cancer progression, where altered endothelial behavior supports tumor angiogenesis. The FGD5 antibody allows researchers to quantify expression changes under pathological conditions and explore its regulatory influence on endothelial plasticity.The FGD5 antibody performs well in western blotting, immunofluorescence, and immunohistochemistry, yielding distinct cytoplasmic and membrane-associated staining. NSJ Bioreagents provides this antibody as a validated reagent for consistent performance across model systems. By facilitating detailed analysis of FYVE, RhoGEF, and PH domain-containing protein 5 expression and function, the FGD5 antibody supports vascular biology research and contributes to understanding the molecular mechanisms driving angiogenesis and endothelial cell dynamics.